US2022281924A1PendingUtilityA1
Engineered hepatitis b core polypeptide
Assignee: UNIV LELAND STANFORD JUNIORPriority: Dec 28, 2018Filed: Jan 21, 2022Published: Sep 8, 2022
Est. expiryDec 28, 2038(~12.4 yrs left)· nominal 20-yr term from priority
C12N 2730/10122C07K 14/005C07K 14/02C12N 2730/10123C12N 7/00C12N 2730/10142
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Genetically modified HBc polypeptides are provided.
Claims
exact text as granted — not AI-modified1 . A hepatitis B core protein (HBc) polypeptide comprising the addition of a cargo-loading domain from 1 to 15 amino acids in length at the carboxy terminus to enhance uptake and retention of encapsulated cargo.
2 - 3 . (canceled)
4 . The HBc polypeptide of claim 2 or claim 3 , wherein the cargo-loading domain comprises one cysteine residue.
5 . The HBc polypeptide of claim 1 , wherein the cargo-loading domain is selected from RRR; R; IIIC; C; CRC; EEE.
6 . The HBc polypeptide of any of claim 1 , further comprising a C-terminal poly-histidine tag before or after the cargo-loading domain.
7 . The HBc polypeptide of claim 1 , comprising an amino acid substitution at residue A131 to a basic amino acid.
8 . The HBc polypeptide of claim 7 , wherein the substitution is A131K.
9 . The HBc polypeptide of claim 1 , further comprising one or more amino acid substitutions selected from [D29C, R127C]; [T109C, V120C]; [Y132C, N136C]; [Y132C, A137C]; [R133C, N136C]; [R133C, A137C]; [P134C, P135C]; [P134C, N136C]; [P134C, A137C]; and [P135C, N136C].
10 . The HBc polypeptide of claim 9 , wherein the amino acid substitutions are [D29C, R127C, P134C, N136C].
11 . The HBc polypeptide of claim 1 , further comprising amino acid substitutions [T74N, L76M, E77Q, P79Q, S81A].
12 . The HBc polypeptide of any claim 1 , wherein the polypeptide further comprises at least one unnatural amino acid.
13 . The HBc polypeptide of claim 12 , wherein the unnatural amino acid provides a reactant group for Click chemistry reactions.
14 . The HBc polypeptide of claim 13 , wherein the unnatural amino acid is azidohomoalanine, homopropargylglycine, p-acetyl-L-phenylalanine or p-azido-L-phenylalanine.
15 . The HBc polypeptide of claim 14 , further comprising one or more additional moieties conjugated to the unnatural amino acid.
16 . A VLP comprised of HBc polypeptides according to claim 1 .
17 . The VLP of claim 16 , wherein the VLP comprises encapsulated cargo.
18 - 19 . (canceled)
20 . The VLP of claim 17 , wherein the cargo is modified to enhance retention or uptake.
21 . The VLP of claim 20 , wherein the cargo is modified by conjugation to cholesterol.
22 . The VLP of claim 20 , wherein the cargo is modified to add a single sulfhydryl group.
23 . A method of assembling a cargo loaded VLP, the method comprising adding cargo to a solution comprising a polypeptide according to claim 1 , wherein the ionicity is less than 1 M NaCl to trigger VLP self-assembly,
treating the assembled VLP with an oxidizing agent to form disulfide bonds.
24 . (canceled)
25 . A method of assembling a cargo loaded VLP, the method comprising adding cargo to a solution comprising a polypeptide according to claim 1 , wherein the iconicity is greater than 1 M NaCl to trigger VLP self-assembly, and, in addition, the solution comprises at least 10% of an organic solvent.
26 - 27 . (canceled)Join the waitlist — get patent alerts
Track US2022281924A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.